Julia Hallisey, MBA

Julia is Chief Operating Officer and Head of Investor Relations for Asha Therapeutics.

Asha Therapeutics (Asha) is a life sciences company which focuses solely on de novo drug discovery and chemical design, leveraging the ability of its disruptive PRISM™ technology platform to design novel therapeutics for neurological, oncological, and rare diseases with high unmet medical need.

Asha has been selected as a BLUE KNIGHT™ company by Johnson & Johnson Innovation and Biomedical Advanced Research and Development Authority (BARDA). 

BLUE KNIGHT™ is a joint initiative between Johnson & Johnson Innovation - JLABS and BARDA, part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, dedicated to the acceleration of transformative technology and science that will enable a swift and targeted response to evolving threats to public health and safety.

Julia previously served as Director of Strategy and Finance for an early stage healthcare data science company specializing in natural language processing. From 2006 - 2011, she established and led Investor Relations for a global specialty finance company, Aircastle (NYSE: AYR) spun out of Fortress Investment Group (NYSE: FIG). Earlier in her career, Julia worked at a number of leading investment banking and asset management firms including JP Morgan, Credit Suisse, and PGIM.

Julia received her MBA from Harvard Business School and her BA from Smith College. She serves as a Program Advisor for the Harvard Business School MS/MBA Program.